Tucson, AZ, November 17, 2026 — The White House has officially withdrawn the nomination of Dr. Heidi Overton to lead the Food and Drug Administration (FDA).

The decision to retract Dr. Overton’s nomination was attributed to a lack of sufficient support from Senate Republicans. This insufficient backing prevented her from securing the necessary votes for confirmation in the Senate.

Dr. Overton was put forward as a candidate for the top position at the FDA, an agency responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, our nation’s food supply, cosmetics, and products that emit radiation.

The withdrawal means that Dr. Overton will not be appointed to lead the federal agency. The specific reasons for the lack of support from Senate Republicans were not detailed in the provided information. Consequently, her confirmation process has been halted.

The absence of a confirmed head for the FDA can create a leadership vacuum within the agency, potentially impacting its operational continuity and regulatory functions. Further details regarding the White House’s next steps in seeking a nominee for the FDA leadership position were not immediately available.


Story summarized from the original created by AP via Scripps News Group on www.kgun9.com, see more information here.

SignalNewsAI
About The Author